U.S regulatory advisors have backed Lucentis for approval in treatment of diabetic macular edema. The FDA panel recommended the agency to approve a 0.5mg and 0.3mg dose of Lucentis in the treatment of DME. The FDA should decide sometime in August on the approval of the drug for as a treatment option. If approved, Lucentis would be the first drug approved for the treatment of diabetic macular edema.
